<DOC>
	<DOCNO>NCT00812240</DOCNO>
	<brief_summary>The objective study compare efficacy safety masitinib imatinib patient gastro-intestinal stromal tumour ( GIST ) first line medical treatment .</brief_summary>
	<brief_title>A Phase 3 Study Evaluate Efficacy Safety Masitinib Comparison Imatinib Patients With Gastro-Intestinal Stromal Tumour First Line Medical Treatment</brief_title>
	<detailed_description>GISTs uncommon visceral sarcoma arise predominantly gastro-intestinal tract . Most GIST cell positive c-kit ( CD117 ) , cell surface antigen correspond Stem Cell Factor ( SCF ) receptor . The receptor intracellular tyrosine kinase ( TK ) join juxtamembrane domain . It hypothesize malignant GIST cell harbor mutation c-kit , result activation c-kit cell division tumour growth . Drugs selectively inhibit TKs likely benefit GISTs . Masitinib ( AB1010 ) TK inhibitor , selectively effectively inhibit c-kit . Imatinib also TK inhibitor indicate treatment GIST . It might associate side effect patient might develop resistance treatment time . Based pre-clinical clinical study , masitinib ( AB1010 ) consider good candidate first line treatment patient GIST .</detailed_description>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Histologically proven , metastatic locally advanced non resectable , recurrent post surgery GIST 2 . Na√Øve patient patient previously treat imatinib neoadjuvant/adjuvant relapse imatinib discontinuation 3 . CKit ( CD117 ) positive tumour detect immunohistochemically PDGF positive ckit negative 4 . Man woman , age &gt; 18 year 5 . Man woman childbearing potential , ( enter study menstrual period negative pregnancy test ) must agree use two method ( one patient one partner ) medically acceptable form contraception study 3 month last treatment intake 6 . Patient able willing comply study procedure per protocol 7 . Patient able understand , sign , date write voluntary informed consent form screen visit prior protocolspecific procedure 1 . Patient previously treat tyrosine kinase inhibitor except imatinib case inclusion criterion 2 2 . Patient treat cancer GIST within 5 year enrolment , exception basal cell carcinoma cervical cancer situ 3 . Patient active central nervous system ( CNS ) metastasis history CNS metastasis 4 . Patient grade III/IV cardiac problem define New York Heart Association Criteria . ( i.e . congestive heart failure , myocardial infarction within 6 month baseline ) Patient condition physician judge could detrimental subject participate study ; include clinically important deviation normal clinical laboratory value concurrent medical event Previous treatment 5 . Treatment investigational agent within 4 week prior baseline 6 . Treatment imatinib neoadjuvant/adjuvant therapy within 4 week prior baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Gastro-Intestinal Stromal Tumour</keyword>
	<keyword>GIST</keyword>
	<keyword>non resectable</keyword>
	<keyword>recurrent post-surgery</keyword>
	<keyword>first line treatment</keyword>
	<keyword>metastatic</keyword>
	<keyword>locally advanced</keyword>
</DOC>